TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$7.890

高値

$8.170

安値

$7.470

出来高

2.98M

企業ファンダメンタルズ

時価総額

1.1B

業種

バイオテクノロジー

United States

取引統計

平均出来高

2.68M

取引所

NGM

通貨

USD

52週レンジ

安値 $1.03現在値 $8.010高値 $9.7

関連ニュース

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

もっと見る
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

もっと見る
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

もっと見る
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%

もっと見る
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers